共 14 条
[1]
Hungria V.T.M., Maiolino A., Martinez G., Et al., Observational study of multiple myeloma in Latin America, Ann Hematol., pp. 1-8, (2016)
[2]
Hajek R., Krejci M., Pour L., Adam Z., Multiple Myeloma, Klin Onkol., 24, pp. S10-S13, (2011)
[3]
Thumallapally N., Meshref A., Mousa M., Terjanian T., Solitary plasmacytoma: Population-based analysis of survival trends and effect of various treatment modalities in the USA, BMC Cancer., 17, 1, (2017)
[4]
Rajkumar S.V., Dimopoulos M.A., Palumbo A., Et al., International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol., 15, 12, pp. e538-e548, (2014)
[5]
Mateos M.-V., Hernandez M.-T., Giraldo P., Et al., Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma, N Engl J Med., 369, 5, pp. 438-447, (2013)
[6]
Hus Bal V., Lord C., Replication of Standardized ADOS Domain Scores in the Simons Simplex Collection, Autism Res., 8, 5, pp. 583-592, (2015)
[7]
Zhu Z., Cao H., Chen L., Incomplete Colonic Obstruction Caused by Extramedullary Plasmacytoma, Clin Gastroenterol Hepatol., 15, 3, pp. e69-e70, (2017)
[8]
Rajshenkhar C., Shaji K., Risk Stratification in Multiple myeloma, Ann Hematol Oncol., 2, 6, (2015)
[9]
Durie B.G.M., Salmon S.E., A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival, Cancer, (1975)
[10]
Howell D.A., Warburton F., Ramirez A.-J., Roman E., Smith A.G., Forbes L.J.L., Risk factors and time to symptomatic presentation in leukaemia, lymphoma and myeloma, Br J Cancer, 113, (2015)